Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
- PMID: 32042274
- PMCID: PMC7000548
- DOI: 10.1016/j.rpor.2020.01.002
Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
Abstract
Aim: To analyse the possible relationship between the EQD2(α/β=3Gy) at 2 cm3 of the vagina and late toxicity in vaginal-cuff-brachytherapy (VBT) after external-beam-irradiation (EBRT) for postoperative endometrial carcinoma (EC).
Materials and methods: From 2014 to 2016, 62 postoperative EC patients were treated with EBRT + VBT. The median EBRT dose was 45 Gy (44 Gy-50.4 Gy). VBT involved a single 7 Gy dose. Toxicity was prospectively evaluated using the RTOG score for the rectum and bladder and the objective LENT-SOMA criteria for the vagina. EQD2(α/β = 3Gy) at 2 cm3 of the most exposed part of the vagina was calculated by the sum of the EBRT + VBT dose. Statistics: Boxplot, Student's t and Chi-square tests and ROC curves.
Results: Mean follow-up: 39.2 months (15-68). Late toxicity: bladder:0 patient; rectum:2 patients-G1; Vagina: 26 patients-17G1, 9G2; median EQD2(α/β=3Gy) at 2 cm3 in G0-G1 patients was 70.4 Gy(SD2.36), being 72.5 Gy(SD2.94) for G2p. The boxplot suggested a cut-point identifying the absence of G2: 100 % of G2p received >68 Gy, ROC curves showed an area under the curve of 0.72 (sensitivity of 1 and specificity of 0.15).
Conclusions: Doses >68 Gy EQD2(α/β=3Gy) at 2 cm3 to the most exposed area of the vagina were associated with late G2 vaginal toxicity in postoperative EC patients treated with EBRT + VBT suggesting a very good dose limit to eliminate the risk of G2 late toxicity. The specificity obtained indicates the need for prospective analyses.
Keywords: Brachytherapy; Late vaginal toxicity; Postoperative endometrial cancer.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Figures
References
-
- Nout R.A., Smit V.T., Putter H. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet. 2010;375:816–823. - PubMed
-
- Nout R.A., Putter H., Jurgenliemk-Schulz I.M. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27:3547–3556. - PubMed
-
- Sorbe B., Nordström B., Mäenpää J. Intravaginal brachy-therapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19:873–878. - PubMed
-
- Choo J.J., Scudiere J., Bitterman P., Dickler A., Gown A.M., Zusag T.W. Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment. Brachytherapy. 2005;4(3):236–240. - PubMed
-
- Guinot J.L., Perez-Calatayud J., Azcoaga J.M. Consensus on treatment of endometrium carcinoma with brachytherapy. Clin Transl Oncol. 2012;14:263–270. - PubMed
LinkOut - more resources
Full Text Sources
